Verve Therapeutics (NASDAQ: VERV)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Verve Therapeutics (NASDAQ: VERV) through any online brokerage.
Other companies in Verve Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), Sage Therapeutics (NASDAQ:SAGE), Day One Biopharmaceutical (NASDAQ:DAWN), Ligand Pharmaceuticals (NASDAQ:LGND) and Relay Therapeutics (NASDAQ:RLAY).
The latest price target for Verve Therapeutics (NASDAQ: VERV) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting VERV to fall to within 12 months (a possible -88.76% downside). 50 analyst firms have reported ratings in the last year.
The stock price for Verve Therapeutics (NASDAQ: VERV) is $35.59 last updated August 12, 2022, 8:00 PM UTC.
The next Verve Therapeutics (VERV) dividend date is projected to be Thursday, September 1, 2022.
Verve Therapeutics’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for Verve Therapeutics.
Verve Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.